Skip to main content
BrainCited
Figure 3

Description

Subgroup analysis by intervention type separates the effects of pure omega-3 supplements from the multinutrient Souvenaid formulation on Alzheimer's disease outcomes.

More Figures from This Paper

Forest plot of randomized controlled trials evaluates the pooled effect of omega-3, DHA, and EPA supplementation on cognitive function scores in Alzheimer's disease patients.

Figure 2

Forest plot of randomized controlled trials evaluates the pooled effect of omega-3, DHA, and EPA supplementation on cognitive function scores in Alzheimer's disease patients.

forest_plot
Forest plot assessing the impact of omega-3 supplementation on functional daily living activities in Alzheimer's disease patients across included trials.

Figure 4

Forest plot assessing the impact of omega-3 supplementation on functional daily living activities in Alzheimer's disease patients across included trials.

forest_plot
Risk of bias assessment for included studies is visualized using the Cochrane tool, indicating overall moderate quality of evidence across the meta-analysis.

Figure 5

Risk of bias assessment for included studies is visualized using the Cochrane tool, indicating overall moderate quality of evidence across the meta-analysis.

chart
Funnel plot analysis evaluates publication bias across the studies included in the systematic review of omega-3 fatty acids for Alzheimer's disease.

Figure 6

Funnel plot analysis evaluates publication bias across the studies included in the systematic review of omega-3 fatty acids for Alzheimer's disease.

chart

Figure 3

Forest Plot
663 × 561px · 128.1 KB

Source Paper

The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systematic review and meta-analysis.

Neuropsychopharmacology reports (2024)

PMID: 38924283

DOI: 10.1002/npr2.12455

Cite This Figure

![Figure 3: Subgroup analysis by intervention type separates the effects of pure omega-3 supplements from the multinutrient Souvenaid formulation on Alzheimer's disease outcomes.](https://pdfs.citedhealth.com/figures/38924283/142.png)

> Source: Ernesto Calderon Martinez et al. "The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systemati." *Neuropsychopharmacology reports*, 2024. PMID: [38924283](https://pubmed.ncbi.nlm.nih.gov/38924283/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/38924283/142.png" alt="Subgroup analysis by intervention type separates the effects of pure omega-3 supplements from the multinutrient Souvenaid formulation on Alzheimer's disease outcomes." />
  <figcaption>Figure 3. Subgroup analysis by intervention type separates the effects of pure omega-3 supplements from the multinutrient Souvenaid formulation on Alzheimer's disease outcomes.<br>  Source: Ernesto Calderon Martinez et al. "The effects of omega-3, DHA, EPA, Souvenaid® in Alzheimer's disease: A systemati." <em>Neuropsychopharmacology reports</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38924283/">38924283</a></figcaption>
</figure>

Related Evidence

A
Omega-3 Fatty Acids (DHA/EPA) for Age-Related Cognitive Decline

Grade A · 58 studies